Prevalence of underlying diseases in died cases of COVID-19: A systematic review and meta-analysis

PLoS One. 2020 Oct 23;15(10):e0241265. doi: 10.1371/journal.pone.0241265. eCollection 2020.

Abstract

Introduction: Underlying disease have a critical role in vulnerability of populations for a greater morbidity and mortality when they suffer from COVID-19. The aim of current study is evaluating the prevalence of underlying disease in died people with COVID-19.

Methods: The current study have been conducted according to PRISMA guideline. International database including PubMed, Scopus, Web of Science, Cochrane and google scholar were searched for relevant studies up to 1 June. All relevant articles that reported underlying disease in died cases of COVID-19 were included in the analysis.

Results: After screening and excluding duplicated and irrelevant studies, 32 articles included in the analysis. The most prevalent comorbidities were hypertension, diabetes, cardiovascular disease, liver disease, lung disease, malignancy, cerebrovascular disease, COPD and asthma. Among all reported underlying disease, highest and lowest prevalence was related to hypertension and asthma which were estimated 46% (37% - 55%) and 3% (2%- 6%), respectively.

Conclusion: In summary, underlying disease have a critical role in poor outcomes, severity of disease and high mortality rate of COVID-19 cases. Patients with hypertension, cardiovascular disease and diabetes should be carefully monitored and be aware of health protocols.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Betacoronavirus*
  • COVID-19
  • Cardiovascular Diseases / epidemiology*
  • Comorbidity
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / mortality*
  • Coronavirus Infections / virology
  • Diabetes Mellitus / epidemiology*
  • Humans
  • Hypertension / epidemiology*
  • Pandemics
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / mortality*
  • Pneumonia, Viral / virology
  • Prevalence
  • Risk Factors
  • SARS-CoV-2
  • Severity of Illness Index

Grants and funding

No, we had not received any fees and fund